This article is more than 5 years old. Information may no longer be current.
Top intervention news of November
Cardiology Today’s Intervention compiled a list of the most popular articles posted to Healio.com/Intervention in November. This month, our readers were interested in delayed reperfusion after mechanical left ventricle unloading, CABG vs. PCI in patients with diabetes and multivessel CAD, medical therapies for treatment of peripheral artery disease and more.
Delayed reperfusion after mechanical LV unloading safe, feasible in STEMI
CHICAGO — In the Door-To-Unload in STEMI Pilot Trial, delaying reperfusion for 30 minutes after LV unloading with the Impella CP device (Abiomed) was safe and feasible in patients with anterior STEMI referred for primary PCI.
FREEDOM Follow-On: CABG still bests PCI in diabetes, multivessel CAD
CHICAGO — The final long-term follow-up report from the landmark FREEDOM trial confirms that patients with diabetes who have multivessel CAD live longer with CABG than with PCI with drug-eluting stents, according to a presentation at the American Heart Association Scientific Sessions.
Medical therapies provide options for PAD treatment
LAS VEGAS — In recent years, data have emerged showing a variety of medical therapies can improve outcomes of patients with PAD, according to a session dedicated to pharmacotherapy at VIVA 18.
Read More
Revisiting the Two-Surgeon Rule for TAVR
Read More
Implant successfully repairs dissections caused by angioplasty
LAS VEGAS — An endovascular implant used to repair dissections caused by plain or drug-coated balloons during angioplasty in peripheral procedures was associated with positive outcomes, according to data presented at VIVA 18.
Read More
Role of antithrombotic therapy evolving
BOSTON — The past year has seen much new research about antithrombotic therapy for primary prevention, secondary prevention and after PCI, according to a speaker at the Cardiometabolic Health Congress.
Read More
SENTRY: Use of bioconvertible IVC filter safe, effective at 2 years
LAS VEGAS — Use of a bioconvertible inferior vena cava filter in patients with pulmonary embolism conferred few adverse events and a high bioconversion rate at 2 years, according to findings from the SENTRY study presented at VIVA 18.
SURTAVI results confirmed: TAVR similar to surgery in intermediate-risk patients
SAN DIEGO — A final analysis of 24-month results from the SURTAVI trial confirmed interim findings that TAVR with a self-expanding bioprosthesis had similar outcomes vs. surgical AVR in patients at intermediate risk for surgery.
Careful medication selection required for PAD with diabetes
LAS VEGAS — Standard therapies for PAD are often not as effective if the patient also has diabetes, in which case additional pharmacotherapy may be required, according to two speakers at VIVA 18.
DCB remains superior to PTA at 5 years
LAS VEGAS — A DCB conferred a lower rate of clinically driven target lesion revascularization at 5 years compared with percutaneous transluminal angioplasty in patients with PAD, according to the final results of the IN.PACT SFA study presented at VIVA 18.